Natera (NTRA) Stock Forecast & Price Target

Natera Inc. is poised for significant revenue growth, particularly from its Signatera product, which has shown a remarkable 54% year-over-year increase in molecular residual disease testing volumes. The company is also actively seeking to expand reimbursement coverage across various cancer types, which is anticipated to enhance both average selling prices and gross margins for Signatera. In addition to surpassing revenue expectations by approximately $80 million in Q3, Natera has raised its financial guidance for 2025 by $160 million, reflecting a strong outlook for the company's continued growth.

Natera is facing significant challenges that could negatively impact its financial performance as margins erode due to pricing pressures from in-network reductions and the expansion of its target addressable market (TAM) to include average-risk patients. The company may encounter further setbacks related to regulatory hurdles, reimbursement issues, and delays in product launches, all of which could adversely affect investor sentiment and stock valuation. Additionally, competition from companies like Guardant Health, particularly in overseas markets, may limit Natera's growth potential if they fail to secure adequate reimbursement coverage for their offerings.